Cargando…

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

Persistent circadian rhythm of bone turnover in bone metastatic breast cancer suggests greater skeletal retention of bisphosphonates if administered in the night. We assessed differential effects of night vs morning administration of zoledronic acid (ZA) on bone turnover. Forty-four breast cancer pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410114/ https://www.ncbi.nlm.nih.gov/pubmed/18506177 http://dx.doi.org/10.1038/sj.bjc.6604390

Ejemplares similares

Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer
por: Bottini, A, et al.
Publicado: (2003)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
por: Fox, Stephen B, et al.
Publicado: (2011)

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
por: Berruti, A., et al.
Publicado: (1996)

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
por: Bottini, A, et al.
Publicado: (2001)

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
por: Berruti, A, et al.
Publicado: (2005)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
por: Milani, Manuela, et al.
Publicado: (2017)

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
por: Tampellini, M., et al.
Publicado: (1997)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Disruption of PTH Receptor 1 in T Cells Protects against PTH-Induced Bone Loss
por: Tawfeek, Hesham, et al.
Publicado: (2010)

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
por: Berruti, A, et al.
Publicado: (1999)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

The effect of zoledronate during bone healing
por: Matos, Marcos Almeida, et al.
Publicado: (2010)

Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
por: O'Brien, Charles A., et al.
Publicado: (2008)

Morning, noon, and night /
por: Cozzens, James Gould, 1903-1978
Publicado: (1968)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
por: Giveon, Sharon, et al.
Publicado: (2023)

Zoledronic acid in the management of metastatic bone disease
por: Polascik, Thomas J, et al.
Publicado: (2008)

Bone structure and remodelling in stroke patients: Early effects of zoledronate()
por: Poole, Kenneth E.S., et al.
Publicado: (2009)

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
por: Doyle, N., et al.
Publicado: (2017)

Saturday night and Sunday morning :
por: Sillitoe, Alan, et al.
Publicado: (1968)

Zoledronic acid for prevention of bone loss in patients receiving bariatric surgery
por: Liu, Yi, et al.
Publicado: (2021)

PTH Receptor Signaling in Osteocytes Governs Periosteal Bone Formation and Intracortical Remodeling
por: Rhee, Yumie, et al.
Publicado: (2011)

Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats
por: Shimizu, T., et al.
Publicado: (2017)

PTH-Induced Bone Regeneration and Vascular Modulation Are Both Dependent on Endothelial Signaling
por: Cohn-Schwartz, Doron, et al.
Publicado: (2022)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

FGF2 crosstalk with Wnt signaling in mediating the anabolic action of PTH on bone formation
por: Xiao, Liping, et al.
Publicado: (2018)

Interactome of PTH-Regulated miRNAs and Their Predicted Target Genes for Investigating the Epigenetic Effects of PTH (1–34) in Bone Metabolism
por: Vrščaj, Lucija Ana, et al.
Publicado: (2022)

Modifications in Bone Matrix of Estrogen-Deficient Rats Treated with Intermittent PTH
por: Pacheco-Costa, Rafael, et al.
Publicado: (2015)

SLPI is a critical mediator that controls PTH-induced bone formation
por: Morimoto, Akito, et al.
Publicado: (2021)

Determinants of Low Bone Turnover in Type 2 Diabetes-the Role of PTH
por: Vavanikunnel, Janina, et al.
Publicado: (2022)

Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT
por: Brouwers, J. E. M., et al.
Publicado: (2009)

Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling
por: Pawlak, Krystyna, et al.
Publicado: (2021)

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2019)

Functionalization of Octacalcium Phosphate Bone Graft with Cisplatin and Zoledronic Acid: Physicochemical and Bioactive Properties
por: Kuvshinova, Ekaterina A., et al.
Publicado: (2023)

PTH 1-34 promoted bone formation by regulating iron metabolism in unloading-induced bone loss
por: Che, Jingmin, et al.
Publicado: (2023)

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
por: Koukourakis, M I, et al.
Publicado: (2014)

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
por: Hadji, P., et al.
Publicado: (2012)

Controlled Delivery of Zoledronate Improved Bone Formation Locally In Vivo
por: Gou, Wenlong, et al.
Publicado: (2014)

Low Bone Turnover and Low BMD in Down Syndrome: Effect of Intermittent PTH Treatment
por: Fowler, Tristan W., et al.
Publicado: (2012)

Amphiregulin-EGFR Signaling Mediates the Migration of Bone Marrow Mesenchymal Progenitors toward PTH-Stimulated Osteoblasts and Osteocytes
por: Zhu, Ji, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dia7ic7lk4re73plo7dolpsls8